Physician profile

Jerry M Franklin

Cardiovascular Disease · Franklin, TN

NPI 1942203849

$1,349.66

in general payments reported to CMS, 2019-2025

8 companies · none reported in 2025

See the full distribution for Cardiovascular Disease

Payments by year

General payments by program year, as reported to CMS.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Boehringer Ingelheim Pharmaceuticals, INC. $646.17 2019-2021
Amgen INC. $270.83 2019-2020
Zoll Services LLC (A/K/A Zoll Lifecor Corp) $133.63 2019-2020
Janssen Pharmaceuticals, INC $127.43 2019-2020
Sanofi-Aventis U.S. LLC $89.78 2019
Novartis Pharmaceuticals Corporation $44.85 2019-2020
Boston Scientific Corporation $19.17 2020
Astrazeneca Pharmaceuticals LP $17.80 2020

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Jerry M Franklin

$1,349.66

in general payments reported 2019-2025

Years
2019-2021
Top company
Boehringer Ingelheim Pharmaceuticals, INC.

https://glasscript.com/doctor/224058/jerry-m-franklin

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.